DRI Healthcare Trust
18.49
CAD
+0.01
(+0.05%)
ISIN
CA23344H1091
CUSIP
23344H109
Return %
Stock
S&P 500
1Y
25.02
14.20
3Y
73.94
81.12
5Y
117.53
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Ali Hedayat
- Full Time Employees
- 32
- Sector
- Miscellaneous
- Industry
- Investment trusts
- Address
- 100 King Street West Toronto ON Canada M5X 1B1
- IPO Date
- Feb 11, 2021
- Website
- drihealthcare.com
- Similar Companies
- Business
- DRI Healthcare Trust is a pharmaceutical royalty monetization company that provides capital to inventors, academic institutions, and biopharma companies to advance innovation in life sciences. The Trust builds and manages a diversified portfolio of royalty streams tied to the sales of pharmaceutical products, generating recurring cash royalties for unitholders and deploying capital to support continued drug development and commercialization. Main products and services - Royalty monetization program services: acquisition and management of pharmaceutical royalties; structured financings that convert future product sales into immediate capital; ongoing revenue collection and administration of royalty streams - Portfolio management and asset oversight: due diligence, valuation, governance, and performance monitoring of royalty assets; asset diversification across therapeutic areas - Capital deployment and financing: equity-like and debt-like structures to fund product development, regulatory approvals, and commercialization efforts; capital structuring to optimize liquidity and yield - Strategic partnerships and licensing arrangements: collaboration with biopharma developers, research institutions, and strategic investors to expand the royalty portfolio and access new product candidates - Reporting and investor relations services: distribution of quarterly and annual performance metrics, cash royalty receipts, and portfolio updates to unitholders Geographic operations and market scope - Global focus with portfolios and royalty assets across multiple regions; operations centered in Canada and international markets to support life sciences financing activity - Active engagement with global pharmaceutical products addressing oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, immunology, and related therapeutic areas - Investor base and partnerships span North America, Europe, and other regions where pharmaceutical innovation and royalty monetization opportunities exist Founding and headquarters - Founded in 2020 - Headquarters in Toronto, Ontario, Canada Organizational structure and relationships - Parent and affiliate relationships: operates as a dedicated trust with a portfolio of royalty assets; managed by a professional asset manager with internalization of management completed in subsequent years - Substantive portfolio relationships with biopharma innovators and product creators to secure perpetual royalty rights and optimize portfolio performance Latest major changes - Strategic asset expansion and portfolio diversification through new royalty acquisitions and ongoing asset performance improvements - Restructuring and capital-structure refinements to enhance deployment capability and liquidity; broadening the investor base with additional institutional investors - Updates to product scope and therapeutic coverage, including expansion into additional product royalties and expansion of the overall asset portfolio - Achievements in quarterly and annual results reflecting growth in cash royalty receipts and EBITDA contribution from a diversified product slate Industry context and business segments - Industry: pharmaceutical royalties financing and life sciences investment - Business segments: royalty asset acquisitions and monetization; portfolio management and performance analytics; capital deployment and liquidity management; investor communications and treasury management Target markets and customers - Primary customers include biopharma developers, academic institutions, and inventors seeking non-dilutive capital through royalty monetization - Secondary beneficiaries include institutional investors seeking exposure to pharmaceutical royalties and life sciences innovation Subsidiaries and corporate relationships - Operates as a standalone trust with an integrated management framework focusing on royalty portfolios; maintains external relationships with product developers and licensees to facilitate royalty income streams This description reflects DRI Healthcare Trust’s core activities as a global pharmaceutical royalty monetization vehicle, emphasizing its principal products and services, recent strategic shifts, and the geographic and market scope of its operations.